Product
UGT1A1
1 clinical trial
1 indication
Indication
Immune System DisorderClinical trial
A Three-part, Sequential, Non-randomized, Open-label Study Designed to Evaluate the Effect of Oral Belumosudil on UGT1A1, P-gp, BCRP and OATP1B1 Inhibition in the Fed State in Healthy Male SubjectsStatus: Completed, Estimated PCD: 2022-10-20